Sartorius (SARTF) Stock Price, News & Analysis

Company Overview

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.

Key Stats

• Today's Range: $193.79 to $193.79
• 50-Day Range: $187.82 to $218.30
• 52-Week Range: $165.00 to $243.35
• Volume: N/A
• Average Volume: 3 shs
• Market Capitalization: N/A
• P/E Ratio: 130.94
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

SARTF Stock Analysis - Frequently Asked Questions

How have SARTF shares performed this year?

Sartorius' stock was trading at $184.00 at the beginning of the year. Since then, SARTF stock has increased by 5.3% and is now trading at $193.7902.
View the best growth stocks for 2025 here.

How were Sartorius' earnings last quarter?

Sartorius (OTCMKTS:SARTF) issued its quarterly earnings data on Wednesday, April, 16th. The company reported $1.28 earnings per share for the quarter, hitting analysts' consensus estimates of $1.28. The firm earned $959.23 million during the quarter, compared to analyst estimates of $867.08 million. Sartorius had a net margin of 2.76% and a trailing twelve-month return on equity of 7.62%.

Does Sartorius have any subsidiaries?

Sartorius subsidiaries include these companies: Novasep’s chromatography division, ALS Automated Lab Solutions GmbH, Xell AG, CellGenix Inc., WaterSep BioSeparations LLC, BIA Separations, Biological Industries, and more.

How do I buy shares of Sartorius?

Shares of SARTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 4/16/2025
• Today: 6/28/2025
• Next Earnings (Estimated): 7/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SARTF
• Previous Symbol: NASDAQ:SARTF
• CIK: N/A
• Web: www.sartorius.com
• Phone: 495513080
• Fax: 49-55-1308-3289
• Employees: 13,528
• Year Founded: 1870

Profitability

• EPS (Most Recent Fiscal Year): $1.48
• Trailing P/E Ratio: 130.94
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $90.90 million
• Net Margins: 2.76%
• Pretax Margin: 6.16%
• Return on Equity: 7.62%
• Return on Assets: 2.92%

Debt

• Debt-to-Equity Ratio: 1.09
• Current Ratio: 1.46
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: $3.66 billion
• Price / Sales: N/A
• Cash Flow: $29.01 per share
• Price / Cash Flow: 6.68
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.09